Présentation de l'entreprise
Aurinia Pharmaceuticals Inc. operates as a biopharmaceutical entity dedicated to delivering therapeutic solutions for individuals suffering from autoimmune diseases characterized by significant unmet medical needs, specifically targeting markets in the United States and Japan. The company functions within the broader Healthcare sector and the specialized industry of Biotechnology, a classification that defines its reliance on research and development to create novel biological agents for patient care. As of the latest available data, the company holds a market capitalization of $2.11B and generates annual revenue of $283.06M, employing a workforce of 128 individuals to execute its operational strategy. These financial metrics collectively indicate a substantial enterprise value that reflects a mature stage of commercialization for its core product portfolio, suggesting the company has achieved significant scale in translating clinical potential into tangible market revenue.
Santé financière
The company reported revenue of $283.06M over the trailing twelve months, with a corresponding net income of $287.20M and an EBITDA of $135.71M. The fact that net income exceeds the reported revenue figure reveals a highly efficient cost structure where non-operating income or specific accounting adjustments significantly contribute to the bottom line, resulting in a profit margin that exceeds 100%. Aurinia maintains robust financial flexibility with free cash flow standing at $91.41M, a figure that demonstrates the entity's ability to fund operations and potential strategic initiatives without relying solely on external capital markets. Profitability is further underscored by a gross margin of 77.0%, an operating margin of 55.7%, and a profit margin of 101.5%, indicating that the company retains a substantial portion of revenue after covering direct production costs and operational expenses. In terms of capital structure, the company holds cash reserves of $397.94M against total debt of $74.81M, while maintaining a debt-to-equity ratio of 12.87, which highlights a balance sheet that is heavily weighted toward equity financing rather than leveraged debt. Liquidity is exceptionally strong, evidenced by a current ratio of 5.25, signifying that current assets are more than five times the value of current liabilities, thereby ensuring ample coverage for short-term obligations. Return on equity stands at 59.9% and return on assets is 11.2%, metrics that collectively reveal a highly effective management team capable of generating substantial returns on the capital invested by shareholders and deployed across the asset base.
Évaluation de la valorisation
The stock carries a trailing P/E ratio of 7.68 and a forward P/E of 19.03, implying that the market expects a significant expansion in earnings that will nearly double the current multiple over the coming year. The price-to-book ratio is recorded at 3.62, indicating that the market values the company at a premium of 3.62 times its book value, reflecting confidence in the intangible assets and future revenue streams inherent to its biotechnology business model. Alternative valuation metrics, including a price-to-sales ratio of 7.46 and an EV/EBITDA of 13.19, suggest that investors are pricing the company based on its sales growth potential and earnings power relative to enterprise value, rather than just historical profitability. Over the past year, the stock price has fluctuated between a low of $6.83 and a high of $16.54, with the current trading position situated below the 52-week high but well above the recent lows, highlighting the volatility inherent in the biotech sector. The beta value of 1.52 indicates that the stock's price volatility is significantly higher than that of the broader market, meaning that price movements will likely be amplified relative to general market shifts.
Growth & Income
Revenue growth year-over-year stands at 28.8%, while earnings growth year-over-year is reported at 15073.2%, demonstrating that earnings are expanding at a rate vastly disproportionate to revenue growth, likely driven by one-time gains or significant margin expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the entity retains all of its earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. This strategy prioritizes long-term asset growth and pipeline expansion over immediate income generation for investors, aligning capital deployment with the high-risk, high-reward profile typical of biotechnology firms. The overall growth and income profile is characterized by exceptional top-line expansion and explosive earnings growth, supported by a capital allocation strategy focused entirely on sustaining innovation and capturing market share in the autoimmune disease space.